The global threat of counterfeit drugs : why industry and governments must communicate the dangers

This article suggests that many pharmaceutical companies and governments are reluctant to publicise the problem of counterfeit medicines to health staff and the public. It recommends mandatory reporting to governmental authorities, which should have a legal duty to investigate, issue appropriate public warnings, and share information across borders